|
1
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: From the perspectives of public health
problem to tumor biology. J Gastroenterol. 44:96–101. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux
M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab
plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J
Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu AX, Finn RS, Edeline J, Cattan S,
Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A,
et al: Pembrolizumab in patients with advanced hepatocellular
carcinoma previously treated with sorafenib (KEYNOTE-224): A
non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Becht R, Kiełbowski K and Wasilewicz MP:
New opportunities in the systemic treatment of hepatocellular
carcinoma-today and tomorrow. Int J Mol Sci. 25:14562024.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abou-Alfa GK, Lau G, Kudo M, Chan SL,
Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Van Dao T, De
Toni EN, et al: Tremelimumab plus Durvalumab in unresectable
hepatocellular carcinoma. NEJM Evid. 1:EVIDoa21000702022.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Locy H, de Mey S, de Mey W, De Ridder M,
Thielemans K and Maenhout SK: Immunomodulation of the tumor
microenvironment: Turn foe into friend. Front Immunol. 9:29092018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cabanillas ME and Habra MA: Lenvatinib:
Role in thyroid cancer and other solid tumors. Cancer Treat Rev.
42:47–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamauchi M, Ono A, Amioka K, Fujii Y,
Nakahara H, Teraoka Y, Uchikawa S, Fujino H, Nakahara T, Murakami
E, et al: Lenvatinib activates anti-tumor immunity by suppressing
immunoinhibitory infiltrates in the tumor microenvironment of
advanced hepatocellular carcinoma. Commun Med (Lond). 3:1522023.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oberg HH, Wesch D, Kalyan S and Kabelitz
D: Regulatory interactions between neutrophils, tumor cells and T
cells. Front Immunol. 10:16902019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Valero C, Lee M, Hoen D, Weiss K, Kelly
DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, et al:
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden
as biomarkers of tumor response to immune checkpoint inhibitors.
Nat Commun. 12:7292021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ding PR, An X, Zhang RX, Fang YJ, Li LR,
Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative
neutrophil to lymphocyte ratio predicts risk of recurrence
following curative resection for stage IIA colon cancer. Int J
Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu N, Jian Y, Wang Y and Tian W:
Evaluation of neutrophil-to-lymphocyte ratio and calcitonin
concentration for predicting lymph node metastasis and distant
metastasis in patients with medullary thyroid cancer. Mol Clin
Oncol. 6:629–634. 2018.PubMed/NCBI
|
|
16
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moschetta M, Uccello M, Kasenda B, Mak G,
McClelland A, Boussios S, Forster M and Arkenau HT: Dynamics of
neutrophils-to-lymphocyte ratio predict outcomes of PD-1/PD-L1
blockade. Biomed Res Int. 2017:15068242017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han
SW, Im SA, Kim TY and Bang YJ: Neutrophil-to-lymphocyte ratio,
platelet-to-lymphocyte ratio, and their dynamic changes during
chemotherapy is useful to predict a more accurate prognosis of
advanced biliary tract cancer. Oncotarget. 8:2329–2341. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Soda H, Ogawara D, Fukuda Y, Tomono H,
Okuno D, Koga S, Taniguchi H, Yoshida M, Harada T, Umemura A, et
al: Dynamics of blood neutrophil-related indices during nivolumab
treatment may be associated with response to salvage chemotherapy
for non-small cell lung cancer: A hypothesis-generating study.
Thorac Cancer. 10:341–346. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie X, Liu J, Yang H, Chen H, Zhou S, Lin
H, Liao Z, Ding Y, Ling L and Wang X: Prognostic value of baseline
neutrophil-to-lymphocyte ratio in outcome of immune checkpoint
inhibitors. Cancer Invest. 37:265–274. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin J, Yang L, Liu D and Li W: Association
of the neutrophil to lymphocyte ratio and clinical outcomes in
patients with lung cancer receiving immunotherapy: A meta-analysis.
BMJ Open. 10:e0350312020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang N, Jiang J, Tang S and Sun G:
Predictive value of neutrophil-lymphocyte ratio and
platelet-lymphocyte ratio in non-small cell lung cancer patients
treated with immune checkpoint inhibitors: A meta-analysis. Int
Immunopharmacol. 85:1066772020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang M, Canzoniero JV, Rosner S, Zhang G,
White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, et al:
Peripheral blood immune cell dynamics reflect antitumor immune
responses and predict clinical response to immunotherapy. J
Immunother Cancer. 10:e0046882022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Japanese translation of common terminology
criteria for adverse events (CTCAE) version 4.0. JCOG. 2009.
|
|
25
|
Lencioni R and Llovet JM: Modified RECIST
(mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis.
30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuwano A, Yada M, Miyazaki Y, Tanaka K,
Kurosaka K, Ohishi Y, Masumoto A and Motomura K: Tumor-infiltrating
CD8+ T cells as a biomarker for chemotherapy efficacy in
unresectable hepatocellular carcinoma. Oncol Lett. 25:2592023.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Montironi C, Castet F, Haber PK, Pinyol R,
Torres-Martin M, Torrens L, Mesropian A, Wang H, Puigvehi M, Maeda
M, et al: Inflamed and non-inflamed classes of HCC: A revised
immunogenomic classification. Gut. 72:129–140. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao X, Huang H, Wang Y, Pan C, Yin S, Zhou
L and Zheng S: Tumor immune microenvironment characterization in
hepatocellular carcinoma identifies four prognostic and
immunotherapeutically relevant subclasses. Front Oncol.
10:6105132021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramjiawan RR, Griffioen AW and Duda DG:
Anti-angiogenesis for cancer revisited: Is there a role for
combinations with immunotherapy? Angiogenesis. 20:185–204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hegde PS, Wallin JJ and Mancao C:
Predictive markers of anti-VEGF and emerging role of angiogenesis
inhibitors as immunotherapeutics. Semin Cancer Biol. 52:117–124.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kwilas AR, Donahue RN, Tsang KY and Hodge
JW: Immune consequences of tyrosine kinase inhibitors that
synergize with cancer immunotherapy. Cancer Cell Microenviron.
2:e6772015.PubMed/NCBI
|
|
32
|
Sprinzl MF, Reisinger F, Puschnik A,
Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A,
Galle PR, Schuchmann M, et al: Sorafenib perpetuates cellular
anticancer effector functions by modulating the crosstalk between
macrophages and natural killer cells. Hepatology. 57:2358–2368.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei X, Tang C, Lu X, Liu R, Zhou M, He D,
Zheng D, Sun C and Wu Z: MiR-101 targets DUSP1 to regulate the
TGF-β secretion in sorafenib inhibits macrophage-induced growth of
hepatocarcinoma. Oncotarget. 6:18389–18405. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Farsaci B, Donahue RN, Coplin MA, Grenga
I, Lepone LM, Molinolo AA and Hodge JW: Immune consequences of
decreasing tumor vasculature with antiangiogenic tyrosine kinase
inhibitors in combination with therapeutic vaccines. Cancer Immunol
Res. 2:1090–1102. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Romero AI, Chaput N, Poirier-Colame V,
Rusakiewicz S, Jacquelot N, Chaba K, Mortier E, Jacques Y,
Caillat-Zucman S, Flament C, et al: Regulation of CD4(+)NKG2D(+)
Th1 cells in patients with metastatic melanoma treated with
sorafenib: Role of IL-15Rα and NKG2D triggering. Cancer Res.
74:68–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sunay MM, Foote JB, Leatherman JM, Edwards
JP, Armstrong TD, Nirschl CJ, Hicks J and Emens LA: Sorafenib
combined with HER-2 targeted vaccination can promote effective T
cell immunity in vivo. Int Immunopharmacol. 46:112–123. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chuang HY, Chang YF, Liu RS and Hwang JJ:
Serial low doses of sorafenib enhance therapeutic efficacy of
adoptive T cell therapy in a murine model by improving tumor
microenvironment. PLoS One. 9:e1099922014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen ML, Yan BS, Lu WC, Chen MH, Yu SL,
Yang PC and Cheng AL: Sorafenib relieves cell-intrinsic and
cell-extrinsic inhibitions of effector T cells in tumor
microenvironment to augment antitumor immunity. Int J Cancer.
134:319–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cabrera R, Ararat M, Xu Y, Brusko T,
Wasserfall C, Atkinson MA, Chang LJ, Liu C and Nelson DR: Immune
modulation of effector CD4+ and regulatory T cell function by
sorafenib in patients with hepatocellular carcinoma. Cancer Immunol
Immunother. 62:737–746. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang CJ, Yang YH, Chiu CJ, Lu LC, Liao
CC, Liang CW, Hsu CH and Cheng AL: Targeting tumor-infiltrating
Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic
hepatocellular carcinoma. Int J Cancer. 142:1878–1889. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kwilas AR, Ardiani A, Donahue RN, Aftab DT
and Hodge JW: Dual effects of a targeted small-molecule inhibitor
(cabozantinib) on immune-mediated killing of tumor cells and immune
tumor microenvironment permissiveness when combined with a cancer
vaccine. J Transl Med. 12:2942014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kimura T, Kato Y, Ozawa Y, Kodama K, Ito
J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, et al:
Immunomodulatory activity of lenvatinib contributes to antitumor
activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci.
109:3993–4002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W,
Yang X and Wang B: The immunomodulatory activity of lenvatinib
prompts the survival of patients with advanced hepatocellular
carcinoma. Cancer Med. 10:7977–7987. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu M, Zhang X, Gao X, Sun S, Wei X, Hu X,
Huang C, Xu H, Wang B, Zhang W, et al: Lenvatinib enhances T cell
immunity and the efficacy of adoptive chimeric antigen
receptor-modified T cells by decreasing myeloid-derived suppressor
cells in cancer. Pharmacol Res. 174:1058292021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tada T, Kumada T, Hiraoka A, Michitaka K,
Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama
K, et al: Neutrophil-to-lymphocyte ratio is associated with
survival in patients with unresectable hepatocellular carcinoma
treated with lenvatinib. Liver Int. 40:968–976. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Alkhouri N, Morris-Stiff G, Campbell C,
Lopez R, Tamimi TA, Yerian L, Zein NN and Feldstein AE: Neutrophil
to lymphocyte ratio: A new marker for predicting steatohepatitis
and fibrosis in patients with nonalcoholic fatty liver disease.
Liver Int. 32:297–302. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wróblewska A, Lorenc B, Cheba M, Bielawski
KP and Sikorska K: Neutrocyte-to-lymphocyte ratio predicts the
presence of a replicative hepatitis C virus strand after therapy
with direct-acting antivirals. Clin Exp Med. 19:401–406. 2019.
View Article : Google Scholar : PubMed/NCBI
|
